US Stock MarketDetailed Quotes
BCAX Bicara Therapeutics
- 18.090
- +0.320+1.80%
Close Nov 22 16:00 ET
- 18.090
- 0.0000.00%
Post 16:00 ET
984.38MMarket Cap-16550P/E (TTM)
18.720High17.510Low542.93KVolume17.510Open17.770Pre Close9.95MTurnover3.10%Turnover RatioLossP/E (Static)54.42MShares28.09052wk High1.93P/B316.58MFloat Cap17.41052wk Low--Dividend TTM17.50MShs Float28.090Historical High--Div YieldTTM6.81%Amplitude17.410Historical Low18.320Avg Price1Lot Size
Bicara Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expense | 116.45%20.63M | 5.93%39.89M | 13.69M | 9.53M | 37.66M |
| Selling and administrative expenses | 83.87%4.76M | 46.15%9.27M | --3.13M | --2.59M | --6.34M |
| -General and administrative expense | 83.87%4.76M | 46.15%9.27M | --3.13M | --2.59M | --6.34M |
| Research and development costs | 128.62%15.86M | -2.22%30.62M | --10.56M | --6.94M | --31.31M |
| Operating profit | -116.45%-20.63M | -5.93%-39.89M | -13.69M | -9.53M | -37.66M |
| Net non-operating interest income expense | 24,107.69%3.15M | 1,316.67%1.31M | 1.3M | 13K | -108K |
| Non-operating interest income | 24,107.69%3.15M | 32,750.00%1.31M | --1.3M | --13K | --4K |
| Non-operating interest expense | ---- | --0 | ---- | ---- | --112K |
| Other net income (expense) | -16,656.25%-13.41M | -49K | -13.33M | -80K | |
| Other non- operating income (expenses) | ---- | -16,656.25%-13.41M | ---49K | ---13.33M | ---80K |
| Income before tax | 23.48%-17.48M | -37.35%-51.98M | -12.44M | -22.85M | -37.84M |
| Income tax | 0 | 400.00%5K | 5K | 0 | 1K |
| Net income | 23.48%-17.48M | -37.36%-51.99M | -12.44M | -22.85M | -37.85M |
| Net income continuous Operations | 23.48%-17.48M | -37.36%-51.99M | ---12.44M | ---22.85M | ---37.85M |
| Minority interest income | |||||
| Net income attributable to the parent company | 23.48%-17.48M | -37.36%-51.99M | -12.44M | -22.85M | -37.85M |
| Preferred stock dividends | |||||
| Other preferred stock dividends | |||||
| Net income attributable to common stockholders | 23.48%-17.48M | -37.36%-51.99M | -12.44M | -22.85M | -37.85M |
| Basic earnings per share | -138.02%-1.6 | -37.49%-3.37 | -0.366 | -0.6722 | -2.451 |
| Diluted earnings per share | -138.02%-1.6 | -37.49%-3.37 | -0.366 | -0.6722 | -2.451 |
| Dividend per share | |||||
| Currency Unit | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
